62484-12-2

Basic information

• Product Name: 7-METHOXYQUINAZOLINE-2,4(1H,3H)-DIONE
• Synonyms: 7-METHOXYQUINAZOLINE-2,4(1H,3H)-DIONE;7-Methoxy-2,4(1H,3H)-quinazolinedione;7-Methoxyquinazoline-2,4-diol;7-Methoxy-1,2,3,4-tetrahydroquinazoline-2,4-dione;2,4(1H,3H)-Quinazolinedione, 7-Methoxy-
• CAS NO: 62484-12-2
• Molecular Formula: C9H8N2O3
• Molecular Weight: 192.18
• Mol File: 62484-12-2.mol
• Article Data: 12

Chemical Properties

• Melting Point: 299-301℃
• Appearance: /
• Density: 1.322
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-METHOXYQUINAZOLINE-2,4(1H,3H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-METHOXYQUINAZOLINE-2,4(1H,3H)-DIONE(62484-12-2)
• EPA Substance Registry System: 7-METHOXYQUINAZOLINE-2,4(1H,3H)-DIONE(62484-12-2)

Safety Data

• Hazardous Substances Data: 62484-12-2(Hazardous Substances Data)

Usage

General Description

7-Methoxyquinazoline-2,4(1H,3H)-dione is a chemical compound with the molecular formula C9H6N2O3. It is a quinazoline derivative that has a methoxy group attached to the 7th position of the quinazoline ring and two carbonyl groups at the 2nd and 4th positions. 7-METHOXYQUINAZOLINE-2,4(1H,3H)-DIONE has been studied for its potential pharmacological activities, including antiviral and anticancer properties. It is also used as a building block in the synthesis of various organic compounds. Its chemical structure and properties make it a versatile and useful molecule in medicinal and synthetic chemistry.

Upstream product

• 409315-39-5 4-methoxy-2-ureido-benzoic acid amide 
• 857600-58-9 4-methoxy-2-ureido-benzoic acid 
• 4294-95-5 4-methoxyanthranilic acid 
• 38487-91-1 2-amino-p-anisamide 
• 38469-83-9 4-methoxy-2-nitro-benzonitrile 
• 590-28-3 potassium cyanate 
• 1072895-72-7 bis(pentafluorophenyl)imidodicarbonate 
• 536-90-3 m-Anisidine 
• 57-13-6 urea 
• 124-38-9 carbon dioxide 
• 38487-85-3 4-methoxyanthranilonitrile 

Downstream Products

• 62484-31-5 2,4,-dichloro-7-methoxyquinazoline 

Relevant articles and documents

Synthesis of acyclic nucleoside phosphonates targeting flavin-dependent thymidylate synthase in Mycobacterium tuberculosis

Flavin-Dependent Thymidylate Synthase (FDTS) encoded by ThyX gene was discovered as a new class of thymidylate synthase involved in the de novo synthesis of dTMP named only in 30 % of human pathogenic bacteria. This target was pursed for the development of new antibacterial agents against multiresistant pathogens. We have developed a new class of ANPs based on the mimic of two natural's cofactors (dUMP and FAD) as inhibitors against Mycobacterium tuberculosis ThyX. Several synthetic efforts were performed to optimize regioselective N1-alkylation, cross-coupling metathesis and Sonogashira cross-coupling. Compound 19c showed a poor 31.8% inhibitory effect on ThyX at 200 μM.

SUBSTITUTED QUINAZOLINE DERIVATIVES AS DNA METHYLTRANSFERASE INHIBITORS

The present invention relates to compounds of the following formula (I) and pharmaceutically acceptable salts and solvates thereof, their methods of preparation, their use as a drug, notably in the treatment of cancer, and pharmaceutical compositions containing such compounds.

Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors

Motivated by the pivotal role of CXCR4 as an HIV entry co-receptor, we herein report a de novo hit-to-lead effort on the identification of subnanomolar purine-based CXCR4 antagonists against HIV-1 infection. Compound 24, with an EC50 of 0.5 nM against HIV-1 entry into host cells and an IC50 of 16.4 nM for inhibition of radioligand stromal-derived factor-1α (SDF-1α) binding to CXCR4, was also found to be highly selective against closely related chemokine receptors. We rationalized that compound 24 complementarily interacted with the critical CXCR4 residues that are essential for binding to HIV-1 gp120 V3 loop and subsequent viral entry. Compound 24 showed a 130-fold increase in anti-HIV activity compared to that of the marketed CXCR4 antagonist, AMD3100 (Plerixafor), whereas both compounds exhibited similar potency in mobilization of CXCR4+/CD34+ stem cells at a high dose. Our study offers insight into the design of anti-HIV therapeutics devoid of major interference with SDF-1α function.